Business Wire

Knopp Biosciences Announces Renewal of NIH Blueprint Grant Award for Advancing KCNQ2 Modulators in Epilepsy

Del

Knopp Biosciences LLC today announced the renewal and expansion of its grant award from the National Institutes of Health Blueprint Neurotherapeutics Network to advance novel treatments for epilepsy.

The Phase 2 award under the NIH Small Business Innovation Research (SBIR) program anticipates NIH support of up to $2 million over the next three years of the project, subject to satisfactory completion of milestones. The renewal follows the successful completion of all milestones under a previously awarded Phase 1 grant of $400,000.

Knopp is directing its potassium channel activator program to preclinical and clinical development of small-molecule drug candidates against a validated, anti-seizure pharmaceutical target encoded by the KCNQ2 gene. Knopp intends to advance novel, small-molecule KCNQ2 activators in neonatal epileptic encephalopathy, a rare disorder caused by inherited mutations in the KCNQ2 gene. Neonatal epileptic encephalopathy is characterized by persistent seizures from the beginning of life and profound developmental disability in children for whom conventional anti-seizure medications are insufficient or ineffective.

Knopp President and CEO Michael Bozik, M.D., a neurologist with clinical development expertise in potassium channel modulators, serves as Principal Investigator on the Blueprint grant. "This Phase 2 award recognizes the need to go beyond seizure control to treat the underlying causes of epilepsy,” he said. “We are very pleased with the renewal of the NIH Blueprint grant and its emphasis on innovative approaches in the treatment of severe epilepsies.”

The NIH Blueprint collaboration will support Knopp’s advance into human studies in KCNQ2 neonatal epileptic encephalopathy. "The KCNQ2 community appreciates the recognition of the NIH to support the need for innovation in uncommon conditions like KCNQ2 epilepsy,” said Jim Johnson, president of the KCNQ2 Cure Alliance. He noted that the annual KCNQ2 Cure Family and Professional Summit, underway this week in Boston, “is focused on partnership and innovation in the search for effective treatments.”

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Our clinical-stage small molecule, dexpramipexole, will be entering late-stage clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. Please visit knoppbio.com.

ABOUT KCNQ2 CURE ALLIANCE

KCNQ2 Cure Alliance is a non-profit organization dedicated to raising research funds for KCNQ2 epileptic encephalopathy, a rare and catastrophic form of epilepsy beginning in the first days of life. Please visit kcnq2cure.org.

Knopp’s Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Knopp Biosciences LLC
Tom Petzinger, +1-412-488-1776
tom@knoppbio.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

GE Renewable Energy Launches Cypress Onshore Wind Platform, Designed to Grow, Adapt, Thrive and Lower the Cost of Electricity for Customers24.9.2018 07:00Pressemelding

GE Renewable Energy (NYSE:GE) today launched its new onshore turbine platform, named Cypress, and the next model from that platform, GE’s 5.3-158 turbine. The platform advances the proven technology of GE’s 2MW and 3MW fleets, which serves an installed base of nearly 20GW, while also utilizing architecture and innovations from the 4.8-158 turbine introduced in 2017. Cypress enables significant AEP improvements, increased efficiency in serviceability, improved logistics and siting potential, and ultimately more value for customers. It is designed to scale over time, enabling GE to offer a wider array of power ratings and hub heights to meet customer needs throughout the 5MW range. The platform also offers up to a 50 percent increase in AEP over the life of the platform versus GE’s 3MW turbines. It is the second major technology platform launch of the year for GE, which introduced the Haliade-X offshore turbine platform in March. This press release features multimedia. View the full rele

MarketSight Now Available in Six Languages24.9.2018 06:30Pressemelding

MarketSight, LLC, a leading provider of data analysis and visualization solutions, has just introduced its award-winning solution in several new languages in its version 11.0 release. Originally available only in English, MarketSight is now being offered in French, German, Italian, Portuguese, and Spanish. MarketSight has always offered support for data in any language. With this new release, it becomes one of the only data analysis and visualization platforms for researchers offered with multiple language options. In addition to making MarketSight accessible to new users whose first language is not English, this new release also gives multilingual teams the ability to collaborate much more efficiently. Market research teams, consulting firms, and other global enterprises working in different languages can work on projects simultaneously while using MarketSight in the language they are most comfortable with. They can also share important findings with international clients through the

Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s24.9.2018 05:00Pressemelding

Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s disease (AD) and other neurological diseases, has announced it has expanded its research collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) to test new algorithms for identifying the pre-symptomatic and mild cognitively impaired people most at risk to progress to AD. Under the expanded agreement Cytox will assess genetic risk for accelerated development of AD using its current, commercially available, research use only approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform. AIBL will provide biobank samples together with associated longitudinal data from study research participants clinically diagnosed as cognitively normal, with mild cognitive impairment or with AD. Each subject has confirmed amyloid status

American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13Pressemelding

Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced

Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43Pressemelding

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar

Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41Pressemelding

Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo